Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Biological bases for a possible effect of cannabidiol in Parkinson's disease

Full text
Author(s):
Ferreira, Nilson C. [1, 2] ; Campos, Alline C. [1] ; Guimaraes, Francisco S. [1] ; Del-Bel, Elaine [2] ; Zimmermann, Patricia M. da R. [3] ; Brum Junior, Liberato [3] ; Hallak, Jaime E. [4] ; Crippa, Jose A. [4] ; Zuardi, Antonio W. [4]
Total Authors: 9
Affiliation:
[1] Univ Sao Paulo, FMRP, Dept Farmacol, Ribeirao Preto, SP - Brazil
[2] Univ Sao Paulo, Dept Morfol Fisiol & Patol Bas, FORP, Ribeirao Preto, SP - Brazil
[3] Prati Donaduzzi & Cia Ltda, Toledo, PR - Brazil
[4] Univ Sao Paulo, Dept Neurociencias & Ciencias Comportamento, FMRP, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, SP - Brazil
Total Affiliations: 4
Document type: Journal article
Source: Revista Brasileira de Psiquiatria; v. 42, n. 2, p. 218-224, MAR-APR 2020.
Web of Science Citations: 2
Abstract

Current pharmacotherapy of Parkinson's disease (PD) is palliative and unable to modify the progression of neurodegeneration. Treatments that can improve patients' quality of life with fewer side effects are needed, but not yet available. Cannabidiol (CBD), the major non-psychotomimetic constituent of cannabis, has received considerable research attention in the last decade. In this context, we aimed to critically review the literature on potential therapeutic effects of CBD in PD and discuss clinical and preclinical evidence supporting the putative neuroprotective mechanisms of CBD. We searched MEDLINE (via PubMed) for indexed articles published in English from inception to 2019. The following keywords were used: cannabis; cannabidiol and neuroprotection; endocannabinoids and basal ganglia; Parkinson's animal models; Parkinson's history; Parkinson's and cannabidiol. Few studies addressed the biological bases for the purported effects of CBD on PD. Six preclinical studies showed neuroprotective effects, while three targeted the antidyskinetic effects of CBD. Three human studies have tested CBD in patients with PD: an open-label study, a case series, and a randomized controlled trial. These studies reported therapeutic effects of CBD on non-motor symptoms. Additional research is needed to elucidate the potential effectiveness of CBD in PD and the underlying mechanisms involved. (AU)

FAPESP's process: 15/05551-0 - Investigation of the involvement of endocannabinoid system on behavioral and plastic effects of antidepressant drugs
Grantee:Alline Cristina de Campos
Support Opportunities: Research Grants - Young Investigators Grants